A Mab A Case Study In Bioprocess Development Online

Protein A is the gold standard for Mab capture. For Mab-X, the team loads clarified harvest at 400 cm/h onto a MabSelect PrismA column.

Problem: High turbidity in the load causes column fouling and pressure spikes >3 bar.

Countermeasure: Depth filtration (3.0 µm to 0.2 µm) followed by a 0.1 µm pre-filter. The team also introduces a low-pH hold step (pH 3.7 for 60 minutes) before loading to precipitate some HCPs, which are then removed by a second depth filter.

Result: Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%.

A Mab’s high concentration (20 g/L intermediate) posed a challenge. Standard 20 nm filters fouled rapidly. The solution: Planova 20N with pre-filtration using 0.1 µm and operation at constant pressure (2 bar). Flux dropped only 30% over 4 hours, acceptable for GMP.

No bioprocess case study is complete without analytics. The Mab-X team implements a real-time process analytical technology (PAT) framework: A Mab A Case Study In Bioprocess Development

One critical insight: Routine HCP ELISA does not detect a specific CHO protein (Cathepsin D) that co-elutes with Mab-X during AEX. The team adds a secondary orthogonal method (LC-MS/MS) to verify HCP clearance.

| Component | Cost per gram mAb | |-----------|------------------| | Media & feeds | $18 | | Protein A resin (reused 50 cycles) | $12 | | Polishing resins & buffers | $8 | | Filtration (depth, virus, UF) | $7 | | Labor & QC | $15 | | Total COGs | $60 / g |

Annual output: 50 kg → $3M direct manufacturing cost.

Out of 500 clones screened, Clone 17B shows the highest specific productivity (qP = 25 pg/cell/day). However, early batch cultures reveal a problematic metabolite profile: high lactate accumulation (4 g/L) and ammonia (2 mM). High lactate inhibits cell growth and reduces final titers.

The Intervention: The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy: Protein A is the gold standard for Mab capture

Outcome: Peak viable cell density increases from 8 to 22 million cells/mL. Final Mab-X titers rise from 1.5 g/L to 5.2 g/L. Lactate is capped at 1.2 g/L, significantly reducing osmotic stress.

You have the pure protein. Now, how do you store it? Proteins are fragile; they can denature (unfold) with changes in temperature or pH.

For mAb-X, high-concentration formulation was required for subcutaneous injection (a shot under the skin) rather than an intravenous (IV) drip. This meant packing a lot of protein into a small volume (100 mg/mL).

The Problem: At high concentrations, mAb-X became too viscous (thick and syrupy). This would make it difficult to inject through a thin needle.

The Fix: We conducted an excipient screening study. By introducing a specific ratio of arginine and sucrose, we successfully shielded the protein-protein interactions that caused viscosity. This stabilized the molecule without compromising the shelf life. One critical insight: Routine HCP ELISA does not

Moving from a 2L benchtop bioreactor to a 2,000L production scale is where physics fights biology.

For mAb-X, the challenge was oxygen transfer. In a small flask, oxygen diffuses easily. In a massive stainless steel tank, the cells in the center can starve for oxygen if mixing isn't perfect.

The Strategy: We moved from a conventional stirred-tank model to implementing a single-use bioreactor (SUB) strategy for the clinical launch.

The outcome was a robust Process Performance Qualification (PPQ) run, where the culture achieved a final titer of 4.5 g/L—a benchmark that makes the manufacturing economically viable.


IP Phone		SMB IP PBX		Telephony card		Outdoor emergency system		Discontinued products